Thanks to its newly announced COVID-19 antibody therapy candidates, Vir Biotechnology's (NASDAQ: VIR) stock is still up more than 10% from the beginning of May and more than 180% from the start of the year. On top of its recent gains, there's reason to believe that Vir is positioned perfectly for continued growth.
While the company has a long way to go before it reaches profitability, between its low-risk pipeline programs for COVID-19 and a demonstrated competency for preclinical drug development for infectious disease, Vir's future seems bright.
Image source: Getty Images.